Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection

D N Gerding, D W Hecht, T Louie, C E Nord, G H Talbot, O A Cornely, M Buitrago, E Best, S Sambol, J R Osmolski, H Kracker, H H Locher, P Charef, M Wilcox, D N Gerding, D W Hecht, T Louie, C E Nord, G H Talbot, O A Cornely, M Buitrago, E Best, S Sambol, J R Osmolski, H Kracker, H H Locher, P Charef, M Wilcox

Abstract

Objectives: The aim of this study was to evaluate the susceptibilities of Clostridium difficile isolates to cadazolid, a novel antibiotic for the treatment of C. difficile infection.

Methods: Ribotyping and susceptibilities were determined for C. difficile isolates from a multicentre, double-blind, Phase 2 study of oral cadazolid in patients with C. difficile infection (NCT01222702, ClinicalTrials.gov; EudraCT 2010-020941-29, European Clinical Trials Database). Patients were randomized to receive 250, 500 or 1000 mg of cadazolid twice daily or 125 mg of vancomycin four times daily, for 10 days. MICs of cadazolid, vancomycin, fidaxomicin, linezolid and moxifloxacin were determined at baseline for all patients and post-baseline for patients with clinical failure or recurrence, using the agar dilution method.

Results: Seventy-eight of 84 patients had an evaluable toxigenic C. difficile isolate at baseline. The most frequent PCR ribotype was 027 (15.4%). Cadazolid MICs for baseline isolates (including epidemic strain 027) ranged from 0.06 to 0.25 mg/L. Baseline cadazolid MICs were similar to those of fidaxomicin and lower than those of vancomycin, linezolid and moxifloxacin. For each clinical outcome group (clinical cure, clinical failure, sustained clinical response and clinical failure or recurrence), the baseline cadazolid MIC range was 0.06-0.25 mg/L. Mean (min-max) cadazolid faecal concentration (μg/g) on day 5 was 884 (101-2710), 1706 (204-4230) and 3226 (1481-12 600) for the doses 250, 500 and 1000 mg, respectively.

Conclusions: For all cadazolid doses, the faecal concentration was in excess of several thousand-fold the MIC90 for C. difficile. The MIC of cadazolid for all C. difficile isolates, including epidemic strains, was low and in the same narrow range regardless of treatment outcome.

© The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.

Figures

Figure 1.
Figure 1.
Distribution of cadazolid MICs at baseline for pooled cadazolid dosages (mITT analysis set).

References

    1. McDonald LC, Killgore GE, Thompson A et al. . An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433–41.
    1. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7: 526–36.
    1. Burke KE, Lamont JT. Clostridium difficile infection: a worldwide disease. Gut Liver 2014; 8: 1–6.
    1. Jones AM, Kuijper EJ, Wilcox MH. Clostridium difficile: a European perspective. J Infect 2013; 66: 115–28.
    1. Borgmann S, Kist M, Jakobiak T et al. . Increased number of Clostridium difficile infections and prevalence of Clostridium difficile PCR ribotype 001 in southern Germany. Euro Surveill 2008; 13: pii=19057.
    1. Goorhuis A, Bakker D, Corver J et al. . Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008; 47: 1162–70.
    1. De Almeida MN, Heffernan H, Dervan A et al. . Severe Clostridium difficile infection in New Zealand associated with an emerging strain, PCR-ribotype 244. N Z Med J 2013; 16: 9–14.
    1. Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012; 55 Suppl 2: S65–70.
    1. Cornely O, Crook DW, Esposito R et al. . Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12: 281–9.
    1. Louie TJ, Miller MA, Mullane KM et al. . Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422–31.
    1. McFarland LV. Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol 2005; 54: 101–11.
    1. Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011; 8: 17–26.
    1. Shah D, Dang MD, Hasbun R et al. . Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 2010; 8: 555–64.
    1. Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20 Suppl 2: 1–26.
    1. Locher HH, Caspers P, Bruyère T et al. . Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for the treatment of Clostridium difficile infections. Antimicrob Agents Chemother 2014; 58: 901–8.
    1. Locher HH, Seiler P, Chen X et al. . In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for the treatment of Clostridium difficile infections. Antimicrob Agents Chemother 2014; 58: 892–900.
    1. Hecht DW, Osmolski JR, Sambol S et al. . In vitro activity of cadazolid against 209 toxigenic isolates of Clostridium difficile. In: Abstracts of the Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2012. Abstract E-808. American Society for Microbiology, Washington, DC, USA.
    1. Rashid MU, Lozano HM, Weintraub A et al. . In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden. Anaerobe 2013; 20: 32–5.
    1. Chilton CH, Crowther G, Baines S et al. . In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J Antimicrob Chemother 2014; 69: 697–705.
    1. Baldoni D, Gutierrez M, Timmer W et al. . Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. J Antimicrob Chemother 2014; 69: 706–14.
    1. Louie T, Nord CE, Talbot GH et al. . A multicenter, double-blind, randomized, phase 2 study evaluating the novel antibiotic, cadazolid, in subjects with Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 2015; .
    1. Stubbs SL, Brazier JS, O'Neill GL et al. . PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999; 37: 461–3.
    1. Indra A, Huhulescu S, Schneeweis M et al. . Characterization of Clostridium difficile isolates using capillary gel electrophoresis-based PCR ribotyping. J Med Microbiol 2008; 57: 1377–82.
    1. Clabots CR, Johnson S, Bettin KM et al. . Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems. J Clin Microbiol 1993; 31: 1870–5.
    1. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria—Eighth Edition: Approved Standard M11-A8. CLSI, Wayne, PA, USA, 2012.
    1. Gravel D, Miller M, Simor A et al. . Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program study. Clin Infect Dis 2009; 48: 568–76.
    1. Hubert B, Loo VG, Bourgault AM et al. . A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec. Clin Infect Dis 2007; 44: 238–44.
    1. Johnson S, Homann SR, Bettin KM et al. . Treatment of asymptomatic Clostridium difficile carriers with vancomycin, metronidazole, or placebo. Ann Intern Med 1992; 117: 297–302.
    1. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27: 1169–72.
    1. Hecht DW, Galang MA, Sambol SP et al. . In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007; 51: 2716–9.
    1. Aradhyula S, Manian FA, Hafidh SA et al. . Significant absorption of oral vancomycin in a patient with Clostridium difficile colitis and normal renal function. South Med J 2006; 99: 518–20.
    1. Bailey P, Gray H. An elderly woman with ‘red man syndrome’ in association with oral vancomycin therapy: a case report. Cases J 2008; 1: 111.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit